Table 4. AUC, best cut-off, sensitivity, specificity, PPV, NPV, and accuracy at predicting csPCa.
| Variables | AUC | Best cut-off | Sensitivity (%), 95% CI | Specificity (%), 95% CI | PPV (%), 95% CI | NPV (%), 95% CI | Accuracy (%) |
|---|---|---|---|---|---|---|---|
| Age | 0.687 | ≥70.5 | 61.6 (51.3–71.1) | 67.6 (60.1–74.3) | 51.7 (42.4–60.9) | 75.8 (68.2–82.1) | 65.5 |
| PSA | 0.659 | ≥6.315 | 74.7 (64.8–82.7) | 51.7 (44.1–59.2) | 46.5 (38.7–54.6) | 78.4 (69.7–85.3) | 60 |
| TPV | 0.662 | <52.6 | 84.8 (74.8–90.2) | 40.3 (33.1–48.0) | 44.1 (37.0–51.6) | 81.6 (71.6–88.8) | 56 |
| PZV | 0.632 | <23.3 | 72.7 (62.7–81.0) | 46.6 (39.1–54.2) | 43.4 (35.8–51.3) | 75.2 (65.9–82.8) | 56 |
| PZ-PSAD | 0.714 | ≥0.368 | 64.6 (54.3–73.8) | 70.5 (63.0–77.0) | 55.2 (45.7–64.3) | 80.0 (70.6–84.0) | 68.4 |
| TZ-PSAD | 0.717 | ≥0.353 | 71.7 (61.6–80.1) | 66.5 (58.9–73.3) | 54.6 (45.7–63.3) | 80.1 (73.1–86.6) | 68.4 |
| PSAD | 0.745 | ≥0.218 | 59.6 (49.2–69.2) | 81.8 (75.1–87.1) | 64.8 (54.0–74.4) | 78.3 (71.5–83.8) | 73.8 |
AUC, area under the receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value; csPCa, clinically significant prostate cancer; CI, confidence interval; PSA, prostate-specific antigen; TPV, total prostate volume; PZV, peripheral zone volume; PZ-PSAD, peripheral zone prostate-specific antigen density; TZ-PSAD, transition zone prostate-specific antigen density.